Tamuzimod
Colitis, Ulcerative
Oppilan Pharma LtdSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
12 Active assets in the Colitis, Ulcerative cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxygen Jay C. Buckey Jr. | Phase 4 | BB |
Hextend Corewell Health West | Phase 3 | B |
Mesalamine Shire | Phase 3 | B |
Mmx Mesalamine/Mesalazine Shire | Phase 3 | B |
Pembrolizumab Diwakar Davar | Phase 2 | B |
View all 30 →
Same molecule, other indications
Tamuzimod is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →